This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Invasive garlic mustard, Alliaria petiolata, and its allelochemical benzyl isothiocyanate were shown to inhibit the growth of three species of EcM fungi grown on white pine seedlings. Changes in EcM communities can have drastic effects on nutrient uptake and community composition of native trees, with far-reaching ecological ramifications.
=== Sales === Counter-Strike became the first fan-made video game to be released commercially. By July 2001, global retail sales of the game had surpassed 250,000 units. By October 2002, sales had exceeded 1.3 million copies. Sales continued to rise, reaching 1.5 million units and generating $40 million in revenue by February 2003. By August 2004, Counter-Strike had grossed $75 million in revenue and had an estimated two million players worldwide. In the United States, its retail version sold 550,000 copies and earned $15.7 million by August 2006, making it the 22nd best-selling PC game in the country between January 2000 and August 2006. The Xbox version of the game sold 1.5 million copies. As of December 2008, Counter-Strike had sold approximately 4.2 million copies, surpassing all other Valve games except Half-Life and Half-Life 2. A portion of Half-Life sales is often attributed to Counter-Strike since the game was originally available as a modification of Half-Life. Half-Life experienced an unusual increase in sales year-over-year following its release, which Gabe Newell attributed to the popularity of Counter-Strike. He described the release of the mod as one of the best things that could have happened to Half-Life.
Simple plant hormone table with location of synthesis and effects of application — this is the format used in the description templates at bottom of Wikipedia articles about plant hormones. Hormonal Regulation of Gene Expression and Development — Detailed introduction to plant hormones, including genetic information.
=== Sources === Print Bosco, David (2009). Five to Rule Them All: The UN Security Council and the Making of the Modern World. Oxford University Press. ISBN 978-0-19-532876-9. Dallek, Robert (1995). Franklin D. Roosevelt and American Foreign Policy, 1932–1945: With a New Afterword. Oxford University Press. ISBN 978-0-19-982666-7. Gaddis, John Lewis (1972). The United States and the Origins of the Cold War, 1941–1947. Columbia University Press. ISBN 978-0-231-12239-9. Hoopes, Townsend; Brinkley, Douglas (1997). FDR and the Creation of the U.N.. Yale University Press. ISBN 978-0-300-08553-2. Kimball, Warren F. (1991). The Juggler: Franklin Roosevelt as Wartime Statesman. Princeton University Press. ISBN 0-691-03730-2. Ma, Xiaohua (2003). The Sino-American alliance during World War II and the lifting of the Chinese exclusion acts. New York: Routledge. pp. 203–204. ISBN 0-415-94028-1. United States Department of State (1942). "Union of Soviet Socialist Republics". Foreign relations of the United States diplomatic papers, 1942. Europe Volume III. U.S. Government Printing Office. pp. 406–771. Welles, Sumner (January 1951). "Two Roosevelt Decisions: One Debit, One Credit". Foreign Affairs. Vol. 29, no. 2. pp. 182–204. Online "1942: Declaration of The United Nations". United Nations. Archived from the original on May 13, 2016. Retrieved April 21, 2016. "1945: The San Francisco Conference". United Nations. 1945. Archived from the original on October 30, 2015. Retrieved May 16, 2015. Urquhart, Brian (July 16, 1998). "Looking for the Sheriff". New York Review of Books.
Sources: en.wikipedia.org
=== Pathological mechanism === HLA-B27 is the most researched HLA-B allele due to its high relationship with spondyloarthropathies. Although it is not apparent how HLA-B27 promotes disease, theories exist and can be divided between antigen-dependent and antigen-independent categories.
During Mahathir's first tenure from 1981 to 2003, Malaysia experienced significant economic growth and modernisation, with his government promoting industry-wide privatisation and initiating major infrastructure projects, such as the North–South Expressway and the Kuala Lumpur City Centre. His policies were credited with transforming Malaysia into one of Southeast Asia's most dynamic emerging economies. He was a dominant political figure, securing five consecutive general election victories and maintaining leadership of the UMNO despite internal challenges. Mahathir continued pro-bumiputera policies and oversaw Malaysia's relatively swift recovery from the 1997 Asian financial crisis, aided by capital controls and stimulus measures that diverged from IMF prescriptions. As prime minister, he was a strong proponent of Asian values and alternative development models, and he played a prominent role in the Muslim world. In 1987, he ordered the detention of numerous activists under Operation Lalang, and his administration was involved in the 1988 Malaysian constitutional crisis, which raised concerns about judicial independence. He supported a constitutional amendment that stripped the royalty of criminal immunity, a move widely regarded as a legal reform strengthening the rule of law. In 1998, the dismissal of deputy Anwar Ibrahim sparked the Reformasi and became a major point of political debate in Malaysia.
== Biology == Honokiol has been extracted from a number of species of Magnolia native to many regions of the globe. Magnolia grandiflora, which is native to the Southeastern United States, as well as Mexican species like Magnolia dealbata have been found to be sources of honokiol. Traditionally in Asian medicine, the Magnolia biondii, Magnolia obovata, and Magnolia officinalis are commonly used. The compound itself has a spicy odor. Because of its physical properties, honokiol can readily cross the blood–brain barrier and the blood–cerebrospinal fluid barrier. As a result, honokiol is a potentially potent therapy with high bioavailability.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.